MX2009001642A - Methods for the treatment of acute myeloid leukemia. - Google Patents

Methods for the treatment of acute myeloid leukemia.

Info

Publication number
MX2009001642A
MX2009001642A MX2009001642A MX2009001642A MX2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A MX 2009001642 A MX2009001642 A MX 2009001642A
Authority
MX
Mexico
Prior art keywords
cdmab
antibodies
treatment
antigen binding
methods
Prior art date
Application number
MX2009001642A
Other languages
Spanish (es)
Inventor
David S F Young
Daniel S Pereira
John E Dick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009001642A publication Critical patent/MX2009001642A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of isolated monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human hematologic malignancies. The invention further relates to binding assays, which utilize the isolated monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
MX2009001642A 2008-12-23 2009-02-12 Methods for the treatment of acute myeloid leukemia. MX2009001642A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/342,986 US20100158801A1 (en) 2008-12-23 2008-12-23 Methods for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2009001642A true MX2009001642A (en) 2010-06-22

Family

ID=42266423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001642A MX2009001642A (en) 2008-12-23 2009-02-12 Methods for the treatment of acute myeloid leukemia.

Country Status (5)

Country Link
US (1) US20100158801A1 (en)
AU (1) AU2009200498A1 (en)
BR (1) BRPI0901452A2 (en)
CA (1) CA2653163A1 (en)
MX (1) MX2009001642A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699150B (en) 2016-01-08 2022-08-09 科凌生物医疗有限公司 Therapeutic anti-CD 9 antibodies

Also Published As

Publication number Publication date
US20100158801A1 (en) 2010-06-24
AU2009200498A1 (en) 2010-07-08
BRPI0901452A2 (en) 2010-09-14
CA2653163A1 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
EP1732602A4 (en) Cytotoxicity mediation of cells evidencing surface expression of mcsp
HK1175846A1 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
RU2016150377A (en) WEBSITE-SPECIFIC CONJUGATION OF LINKED MEDICINES WITH ANTIBODIES AND OBTAINED BY ADC
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
MX2021014094A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use.
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
JP2008532523A5 (en)
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
EA032908B1 (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins
MX346973B (en) Tumor specific antibodies and uses therefor.
ECSP12012138A (en) ANTI-CD44 MONOCLONIC ANTIBODY BINDING THE HEAD AND NECK SCAMOCELLULAR CARCINOMA
EP1708751A4 (en) Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
MA32288B1 (en) New antibodies useful for cancer treatment
WO2009023955A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd9
MX2009010269A (en) Methods of treating cancer by administering human il-18 combinations.
MX2009007619A (en) Cancerous disease modifying antibodies.
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
MX2009001014A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63.
MX2009007618A (en) Cancerous disease modifying antibodies.
MX2009007617A (en) Cancerous disease modifying antibodies.
MX2009001642A (en) Methods for the treatment of acute myeloid leukemia.
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4

Legal Events

Date Code Title Description
FA Abandonment or withdrawal